Will RVTY Q3 Earnings Reflect Segmental Strength Amid Rising Demand?
RVTY's third-quarter results are likely to reflect strong performance in the Life Sciences segment. However, the Diagnostic segment is set to face challenges in China.
RVTY Collaborates With Sanofi for Early Detection of Type 1 Diabetes
Revvity partners with Sanofi to launch a scalable diagnostic test for early T1D detection, expanding its reach beyond rare diseases.
Revvity Q2: Headwinds From China And Customers, Buy On Weakness
Revvity, Inc.'s focus on high-growth markets like cell and gene therapies and precision medicine positions it for long-term expansion despite near-term challenges. The recent divestiture streamlines Revvity's portfolio, allowing greater investment in specialized diagnostics and software, which are expected to drive future growth. While facing weak academic/government demand and China headwinds, Revvity maintains a strong capital structure and margin expansion potential through cost optimization.
Revvity Stock Sinks on Lowered China Immunodiagnostics Outlook
Revvity (RVTY) was one of the worst-performing stocks in the S&P 500 Monday after the medical device maker said it anticipated a "meaningful pullback" in its immunodiagnostics business in China.
Top Stock Movers Now: Nike, Cheniere Energy, Revvity, and More
U.S. equities were mhigher at midday after President Donald Trump and European Commission President Ursula von der Leyen announced a new trade agreement between the U.S. and the European Union. The Dow Jones Industrial Average, Nasdaq, and S&P 500 all rose.
Revvity, Inc. (RVTY) Q2 2025 Earnings Call Transcript
Revvity, Inc. (NYSE:RVTY ) Q2 2025 Earnings Conference Call July 28, 2025 8:00 AM ET Company Participants Maxwell Krakowiak - Senior VP & CFO Prahlad R. Singh - CEO, President & Director Stephen Barr Willoughby - Senior VP of Investor Relations & Head of ESG Conference Call Participants Daniel Anthony Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Daniel Gregory Brennan - TD Cowen, Research Division Daniel Louis Leonard - UBS Investment Bank, Research Division Douglas Anthony Schenkel - Wolfe Research, LLC Luke England Sergott - Barclays Bank PLC, Research Division Michael Leonidovich Ryskin - BofA Securities, Research Division Patrick Bernard Donnelly - Citigroup Inc., Research Division Puneet Souda - Leerink Partners LLC, Research Division Rachel Marie Vatnsdal Olson - JPMorgan Chase & Co, Research Division Vijay Muniyappa Kumar - Evercore ISI Institutional Equities, Research Division Operator Hello, everybody, and welcome to the Q2 2025 Revvity Earnings Conference Call.
RVTY Posts Q2 Earnings & Sales Beat, Raises '25 Sales View
Revvity's second-quarter results showcase strong growth in its Diagnostics business, along with recovery in Life Sciences segmental sales.
Revvity (RVTY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Revvity (RVTY) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Revvity (RVTY) Surpasses Q2 Earnings and Revenue Estimates
Revvity (RVTY) came out with quarterly earnings of $1.18 per share, beating the Zacks Consensus Estimate of $1.14 per share. This compares to earnings of $1.22 per share a year ago.
Revvity Stock Tumbles After Earnings. What's Dragging on the Shares.
The health sciences company posts better-than-expected adjusted earnings and revenue but trims its guidance.
Why Revvity (RVTY) is Poised to Beat Earnings Estimates Again
Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Revvity Q2 Preview: Can Strong Segments Deliver an Earnings Beat?
RVTY is likely to see another earnings beat as Diagnostics momentum and Signals Software growth offset tariff headwinds.
